On July 20, 2026, Yi-An Chu and Dr. Chen-Huan (Jack) Jan resigned from the Apollomics Inc. Board of Directors, citing no disagreements with the company. Mr. Hung-Hsien Yen was appointed as a Class I director to fill the vacancy, joining the Audit Committee and chairing the Nominating and Corporate Governance Committee. Mr. Yen will receive an annual base retainer of $24,000, a $5,000 Audit Committee fee, and a $10,000 committee chairmanship fee, alongside 500 restricted stock units vesting on September 15, 2026. Apollomics Inc. is a biotechnology company.

Apollomics Inc. received a Nasdaq listing deficiency notice on June 18, 2026, because it failed to meet the minimum $35 million Market Value of Listed Securities requirement. The company also failed to meet alternative Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3). The company has a 180-day compliance period ending December 15, 2026, to regain compliance. Additionally, effective June 11, 2026, the company terminated its Collaboration and License Agreement with Launxp International Co., Ltd. due to a material breach involving an unpaid $3.8 million upfront payment. A dispute resolution process was initiated on June 18, 2026. Apollomics Inc. is a biotechnology company focused on oncology-related drug discovery and development.